Use of Platelet Rich Plasma in the Management of Acute Hamstring Muscle Strain Injury
Acute Hamstring Muscle Strain Injury
About this trial
This is an interventional treatment trial for Acute Hamstring Muscle Strain Injury focused on measuring Platelet rich plasma, Interventional, Randomized, Double-blind
Eligibility Criteria
Inclusion Criteria:
- Acute onset posterior thigh pain
- MRI confirmed Grade I, II hamstring lesions
- < 5 days from injury
- Able to perform Physiotherapy at ASPETAR (5 sessions/week)
- Available for follow-up
- Male
- Age > 18 years
Exclusion Criteria:
- Diabetes, immuno-compromised state
- Overlying skin infection
- Re-injury or Chronic ongoing hamstring injury
- Unwilling to comply with follow up
- Contraindication to MRI
- Needle Phobia
- Bleeding disorder or other medical contraindication to injection
- Medication increasing bleeding risk (e.g. Plavix)
- Concurrent other injury inhibiting rehabilitation
Sites / Locations
- Aspetar; Qatar Orthopaedic and Sports Medicine Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Placebo Comparator
Active Comparator
No Intervention
PPP
PRP
Physiotherapy
Placebo: Platelet Poor Plasma Under sterile conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PPP each, administered by a sports medicine physician (total 3 cc PPP). Following the completion of the injections (treatment or control) physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)
Biological: Platelet Rich Plasma Under sterile ultrasound conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PRP each, administered by a sports medicine physician (total 3 cc PRP). Following the completion of the injections (treatment or control) physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)
These patients will not receive an injection. Following the inclusion physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)